Abstract 15396: Comparative Efficacy and Safety of Apixaban versus Rivaroxaban in Obese Adults with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis
TL;DR
In obese or morbidly obese adults with NVAF, apixaban was associated with lower systemic embolization, myocardial infarction, gastrointestinal hemorrhage, and major bleeding than rivaroxaban, with no significant differences in ischemic stroke, intracranial bleeding, hemorrhagic stroke, or mortality.
Abstract
Introduction/Background: Nonvalvular atrial fibrillation (NVAF) is associated with obesity, and this could impact direct oral anticoagulant exposure and outcomes. This meta-analysis aims to find available evidence that compares apixaban with rivaroxaban in obese adults to treat NVAF. Research Question: Is apixaban superior to rivaroxaban in obese or morbidly obese adults with NVAF in terms of the thromboembolic and safety outcomes? Methods: PubMed, Scopus, Embase, Cochrane, and ClinicalTrials.gov were searched from inception to May 2026. Outcomes were systemic embolization, ischemic stroke, myocardial infarction, intracranial bleeding, hemorrhagic stroke, gastrointestinal hemorrhage, major bleeding, and all-cause mortality. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using Mantel-Haenszel random-effects models. Analyses were conducted using Revman 5.4.0. I 2 was used to assess heterogeneity, and GRADE was used to assess certainty of evidence. Results: Five comparative studies provided data (61,849 participants in total with an age ranging from 62.2±12.0 to 77.7±14.4 years). Statistically significant findings favored apixaban for systemic embolization (RR, 0.80; 95% CI, 0.65-0.99; p=0.04), myocardial infarction (RR, 0.58; 95% CI, 0.38-0.87; p=0.009), gastrointestinal hemorrhage (RR, 0.56; 95% CI, 0.35-0.89; p=0.01), and any major bleeding/major bleeding (RR, 0.58; 95% CI, 0.43-0.80; p=0.0009). The heterogeneity of myocardial infarction, gastrointestinal hemorrhage, and major bleeding was low, moderate, and substantial, respectively (I 2 =0%, I 2 =81%, and I 2 =61%). Statistically non-significant outcomes included ischemic stroke (RR, 0.88; 95% CI, 0.71-1.08; p=0.21), intracranial bleeding/hemorrhage (RR, 0.78; 95% CI, 0.52-1.15; p=0.21), hemorrhagic stroke (RR, 0.73; 95% CI, 0.47-1.15; p=0.17), and all-cause mortality (RR, 1.28; 95% CI, 0.89-1.85; p=0.18). Conclusion: In obese or morbidly obese adults with NVAF, apixaban was associated with lower systemic embolization, myocardial infarction, gastrointestinal hemorrhage, and major bleeding than rivaroxaban, with no significant differences in ischemic stroke, intracranial bleeding, hemorrhagic stroke, or mortality. Overall, apixaban may offer a more favorable effectiveness-safety profile, though findings should be interpreted cautiously given observational evidence and heterogeneity in bleeding outcomes.